Julie Vose, MD, MBA


Drs. Julie Vose and Kieron Dunleavy discuss the state of the art of therapy in diffuse large B cell lymphoma and the lack of novel entrants into the frontline treatment landscape. New clinical trial designs might be necessary to identify the subgroups of patients who may be candidates for novel therapeutic options.